TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27575314

Group type: EXPERIMENTAL
Intervention: Promotora education, Video education, Combined promotora and video education
Number of subjects: 784

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 784
Study: 23676632

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM) acupuncture (AP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional Chinese medicine (verum CHM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo CHM
Number of subjects: 40
Study: 20152665

Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME) during orthodontic treatment in group 1 (25 patients)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Fixed appliances without RME in group 2 (23 patients)
Number of subjects: 48
Study: 18836152

Group type: COMPARATOR
Intervention: Diagnosed diabetes (self-reported diabetes or diabetic medication use; n = 163)
Number of subjects: 1917

Group type: COMPARATOR
Intervention: Undiagnosed diabetes (fasting blood glucose >or=7.0 mmol/L without diagnosed diabetes; n = 55)
Number of subjects: 1917

Group type: COMPARATOR
Intervention: Impaired fasting glucose (fasting blood glucose 5.6-6.9 mmol/L; n = 744)
Number of subjects: 1917

Group type: COMPARATOR
Intervention: Normoglycemics (control group)
Number of subjects: 1917
Study: 16219312

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 12791104

Group type: EXPERIMENTAL
Intervention: Praziquantel (PZQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxamniquine (OXAM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (untreated children)
Number of subjects: 0
Study: 11026393

Group type: EXPERIMENTAL
Intervention: Positive outcomes occurring randomly on 33% of trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive outcomes occurring randomly on 66% of trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Varying number of response alternatives (two, three, or six)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants' scores on Burger and Cooper's 1979 Desirability of Control scale
Number of subjects: 0
Study: 8632540

Group type: EXPERIMENTAL
Intervention: Preoperative M-VAC chemotherapy (2 courses before surgery and 3 courses after surgery)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Postoperative M-VAC chemotherapy (5 adjuvant courses following cystectomy)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Preoperative M-VAC chemotherapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Postoperative M-VAC chemotherapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 1945214

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nylidrin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 60
Study: 6841934

Group type: EXPERIMENTAL
Intervention: Job club program
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normally available services (control)
Number of subjects: 46
Study: 30856210

Group type: EXPERIMENTAL
Intervention: Screening mammography
Number of subjects: 25318

Group type: EXPERIMENTAL
Intervention: Factors associated with higher false-positive recall
Number of subjects: 25318

Group type: EXPERIMENTAL
Intervention: Factors associated with lower risk of false-positive recall
Number of subjects: 25318

Group type: EXPERIMENTAL
Intervention: Further adjustment of percent mammographic density
Number of subjects: 25318
Study: 30095232

Group type: EXPERIMENTAL
Intervention: Immediate intervention (PEERS® intervention)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Delayed intervention group (control)
Number of subjects: 41
Study: 26946729

Group type: EXPERIMENTAL
Intervention: menstrual cycle-based acupuncture therapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: IVF-ET (control group)
Number of subjects: 63
Study: 23235718

Group type: EXPERIMENTAL
Intervention: Low glycemic index diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard diabetic diet
Number of subjects: 20
Study: 22293584

Group type: EXPERIMENTAL
Intervention: Statin + EPA (1,800 mg/day for 6 months)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Statin alone
Number of subjects: 28
Study: 19927132

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 636

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 636
Study: 17353443

Group type: COMPARATOR
Intervention: Fixed lower-energy regimen (150-150-150 J)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Escalating higher-energy regimen (200-300-360 J)
Number of subjects: 221

Group type: COMPARATOR
Intervention: First shock success (Fixed lower)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: First shock success (Escalating higher)
Number of subjects: 221
Study: 16127249

Group type: EXPERIMENTAL
Intervention: Whole body MRI (WB‐MRI)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Bone scintigram (BS)
Number of subjects: 16
Study: 12401596

Group type: EXPERIMENTAL
Intervention: Caudal bupivacaine/neostigmine mixture (0.25% bupivacaine 1 mL/kg + neostigmine 2 micro g/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Caudal bupivacaine (0.25% bupivacaine 1 mL/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Caudal neostigmine (2 micro g/kg in normal saline 1 mL/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Caudal bupivacaine/neostigmine mixture
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Caudal bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Caudal neostigmine
Number of subjects: 60
Study: 10452884

Group type: EXPERIMENTAL
Intervention: Circular Stapled Anastomosis (CSA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Double Stapling Anastomosis (DSA)
Number of subjects: 0
Study: 8560532

Group type: EXPERIMENTAL
Intervention: Amodiaquine (35 mg/kg over 3 days)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Chloroquine (25 mg/kg over 3 days)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Amodiaquine
Number of subjects: 123

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 123
Study: 2128475

Group type: EXPERIMENTAL
Intervention: Auranofin (AF) 6 mg/day
Number of subjects: 121

Group type: COMPARATOR
Intervention: Gold sodium thiomalate (GST) 50 mg/week
Number of subjects: 121

Group type: COMPARATOR
Intervention: Gold sodium thiomalate (GST) 50 mg/month after dose reduction
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Auranofin (AF) 4 mg/day after dose reduction
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Withdrawal rate due to adverse events
Number of subjects: 121
Study: 373665

Group type: EXPERIMENTAL
Intervention: Amitriptyline added to perphenazine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Perphenazine alone
Number of subjects: 35
Study: 31157366

Group type: EXPERIMENTAL
Intervention: High level of PEEP (12 cm H2O with alveolar recruitment maneuvers)
Number of subjects: 2013

Group type: COMPARATOR
Intervention: Low level of PEEP (4 cm H2O)
Number of subjects: 2013
Study: 28345162

Group type: EXPERIMENTAL
Intervention: Lixisenatide (10 µg initially increased weekly by 5 up to 20 µg)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Sitagliptin (50 mg once daily)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 136

Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 136
Study: 26087566

Group type: EXPERIMENTAL
Intervention: Sophora gel (one piece every night for 14 days) and Fluconazole capsules (150 mg, once every three days, four times in total)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Fluconazole capsules (control group)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Sophora gel combined with Fluconazole capsules
Number of subjects: 85
Study: 22837542

Group type: EXPERIMENTAL
Intervention: Early enhanced speech and language therapy after stroke
Number of subjects: 22

Group type: COMPARATOR
Intervention: Employed visitor support
Number of subjects: 22
Study: 21860188

Group type: EXPERIMENTAL
Intervention: Amiodarone (3 mg/kg in 100 ml normal saline)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 56
Study: 19699256

Group type: EXPERIMENTAL
Intervention: Wet-hydrated condition (H)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Dry-dehydrated specimens (DH5s and DH10s)
Number of subjects: 3
Study: 17485450

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 63

Group type: COMPARATOR
Intervention: Morphine, atropine, and suxamethonium
Number of subjects: 63
Study: 14583740

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 50
Study: 11570048

Group type: EXPERIMENTAL
Intervention: Good health
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: Social security and pension
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: Self-care independence
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: Marital satisfaction
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: Good relationship with relatives
Number of subjects: 996
Study: 9593137

Group type: EXPERIMENTAL
Intervention: 600 mg of RMP plus 400 mg of OFLO and 100 mg of MINO
Number of subjects: 20

Group type: COMPARATOR
Intervention: 400 mg of OFLO plus 100 mg of MINO
Number of subjects: 20
Study: 7923315

Group type: EXPERIMENTAL
Intervention: Clebopride (0.5 mg) and simethicone (200 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 3380312

Group type: EXPERIMENTAL
Intervention: Dantrolene sodium (25 mg, twice a day for seven days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30054777

Group type: EXPERIMENTAL
Intervention: event-specific, text message Personalized Drinking Feedback Intervention (TXT PFI)
Number of subjects: 130

Group type: COMPARATOR
Intervention: control condition
Number of subjects: 130
Study: 28774394

Group type: EXPERIMENTAL
Intervention: Bucindolol
Number of subjects: 1358

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1358
Study: 26123388

Group type: EXPERIMENTAL
Intervention: Bilateral feet Cold Pressor Test (CPT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Classic Cold Pressor Test (CPT)
Number of subjects: 24
Study: 23804517

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (gastric bypass or sleeve gastrectomy)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (gastric bypass)
Number of subjects: 14
Study: 21697532

Group type: EXPERIMENTAL
Intervention: MVA85A with EPI vaccines
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: MVA85A alone
Number of subjects: 214

Group type: COMPARATOR
Intervention: EPI vaccines alone
Number of subjects: 214
Study: 19383885

Group type: EXPERIMENTAL
Intervention: Highest quartile of recreational physical activity duration
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Highest quartile of physical activity
Number of subjects: 735

Group type: COMPARATOR
Intervention: High triglycerides (> or =136 mg/dL)
Number of subjects: 735
Study: 16942935

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 58
Study: 15246205

Group type: EXPERIMENTAL
Intervention: Normal protein diet
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-protein diet
Number of subjects: 30
Study: 11348910

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl
Number of subjects: 256

Group type: COMPARATOR
Intervention: Sustained release oral morphine
Number of subjects: 256
Study: 9205818

Group type: EXPERIMENTAL
Intervention: MP suleptanate
Number of subjects: 90

Group type: COMPARATOR
Intervention: MP succinate
Number of subjects: 90
Study: 8489572

Group type: EXPERIMENTAL
Intervention: 200 mg fluconazole suppository
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 25 mg fluconazole suppository
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200 mg and 25 mg fluconazole suppositories
Number of subjects: 0
Study: 3327370

Group type: EXPERIMENTAL
Intervention: Clonazepam (CLN) and Haloperidol (HL)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Haloperidol (HL) and Placebo
Number of subjects: 24
Study: 28961427

Group type: EXPERIMENTAL
Intervention: Naproxen sodium (550 mg) and codeine phosphate (30 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Diclofenac potassium (50 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Benzydamine hydrochloride (50 mg)
Number of subjects: 90
Study: 27697874

Group type: EXPERIMENTAL
Intervention: Day-case cochlear implantation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Inpatient cochlear implantation
Number of subjects: 30
Study: 25118967

Group type: EXPERIMENTAL
Intervention: Rapid HIV testing without brief risk reduction counseling
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Rapid HIV testing with brief risk reduction counseling
Number of subjects: 7

Group type: COMPARATOR
Intervention: Implementation of universal rapid HIV testing without counseling
Number of subjects: 7

Group type: COMPARATOR
Intervention: Implementation of universal rapid HIV testing with counseling
Number of subjects: 7

Group type: COMPARATOR
Intervention: Median start-up costs per clinic without counseling
Number of subjects: 7

Group type: COMPARATOR
Intervention: Median start-up costs per clinic with counseling
Number of subjects: 7
Study: 22581341

Group type: EXPERIMENTAL
Intervention: Hood colonoscopy
Number of subjects: 378

Group type: COMPARATOR
Intervention: Standard examination
Number of subjects: 378
Study: 19536877

Group type: EXPERIMENTAL
Intervention: AVPD
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Other PD
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: No PD
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Any lifetime mood disorder
Number of subjects: 134
Study: 18399022

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 38

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 38
Study: 15805455

Group type: EXPERIMENTAL
Intervention: Active strategy (multifaceted programme including education, discussion, role playing, feedback, and reminders)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Standard dissemination (control group receiving guidelines by mail)
Number of subjects: 113
Study: 12584785

Group type: EXPERIMENTAL
Intervention: Fu'an Liquid (FAL) for retention enema
Number of subjects: 89

Group type: COMPARATOR
Intervention: Conventional therapy of western medicine
Number of subjects: 89
Study: 11188494

Group type: EXPERIMENTAL
Intervention: Pretest-posttest analyses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cross-sectional analyses
Number of subjects: 0
Study: 9174473

Group type: EXPERIMENTAL
Intervention: High-amylose starch diet
Number of subjects: 24
Study: 1283192

Group type: EXPERIMENTAL
Intervention: Nilvadipine (16 mg q.d.)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Hydrochlorothiazide/Triamterene (HCT/T) (25/50 mg q.d.)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Nilvadipine (1 x 8 mg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Enalapril (1 x 10 mg)
Number of subjects: 125
Study: 3574642

Group type: EXPERIMENTAL
Intervention: 1.0 M sodium lactate (5 ml/kg in 5% dextrose/water) over a 20‐min period
Number of subjects: 27

Group type: COMPARATOR
Intervention: 5% dextrose in water
Number of subjects: 27
Study: 30372582

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation with enalapril
Number of subjects: 2529

Group type: COMPARATOR
Intervention: Enalapril alone
Number of subjects: 2529
Study: 26823970

Group type: EXPERIMENTAL
Intervention: Pragmatic advice, manual soft tissue treatment and exercises
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Pragmatic advice, manual soft tissue treatment and exercises plus manipulative therapy
Number of subjects: 237
Study: 24290858

Group type: EXPERIMENTAL
Intervention: 3D-reconstruction group (Group A, n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (Group B, n=20)
Number of subjects: 40
Study: 22662733

Group type: EXPERIMENTAL
Intervention: Individual in-person psychotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychotherapy via video teleconferencing
Number of subjects: 0
Study: 20422879

Group type: EXPERIMENTAL
Intervention: Hyosine N-butyl bromide
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 19045976

Group type: EXPERIMENTAL
Intervention: Acceptance-based behavior therapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Delayed treatment (control)
Number of subjects: 31
Study: 15643534

Group type: EXPERIMENTAL
Intervention: Eccentric training
Number of subjects: 2

Group type: COMPARATOR
Intervention: Concentric training
Number of subjects: 2
Study: 14562015

Group type: EXPERIMENTAL
Intervention: Written feedback plus course
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Course alone
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Written feedback alone
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control
Number of subjects: 160
Study: 10652394

Group type: EXPERIMENTAL
Intervention: Remifentanil/propofol anesthetic
Number of subjects: 80

Group type: COMPARATOR
Intervention: Propofol/fentanyl combination
Number of subjects: 80
Study: 9050095

Group type: EXPERIMENTAL
Intervention: Pressurized aerosol of ipratropium bromide (80 mg single dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Aqueous pump spray of ipratropium bromide (80 mg single dose)
Number of subjects: 20
Study: 30701365

Group type: EXPERIMENTAL
Intervention: Minimally invasive liver resection (LLR)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Open liver resection (OLR)
Number of subjects: 193
Study: 29122196

Group type: EXPERIMENTAL
Intervention: Vibration applied to the low back (3‐min duration) at the 2‐h and 2.25‐h marks
Number of subjects: 18

Group type: COMPARATOR
Intervention: No vibration (control condition)
Number of subjects: 18
Study: 27373347

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) frozen section (FS) before Z0011
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) frozen section (FS) after Z0011
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Axillary lymph node dissection (ALND) post-Z0011
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node positivity
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Nodal upstage in invasive lobular subtype
Number of subjects: 250
Study: 25158633

Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya yoga (active group, n = 11)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Waitlist control (control group, n = 10)
Number of subjects: 21
Study: 22268365

Group type: EXPERIMENTAL
Intervention: Irbesartan (overall treatment)
Number of subjects: 52
Study: 18091016

Group type: EXPERIMENTAL
Intervention: GABA (3 g)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: GABA + Resistance Exercise (EX-GABA)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Resistance Exercise (EX-P)
Number of subjects: 11
Study: 16896048

Group type: EXPERIMENTAL
Intervention: Median ovarian volume >or=3.0 cm3
Number of subjects: 0
Study: 14658966

Group type: EXPERIMENTAL
Intervention: High-dose divalproex sodium
Number of subjects: 71
Study: 10758465

Group type: EXPERIMENTAL
Intervention: Central venous and pulmonary artery catheterization performed awake using local anaesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Central venous and pulmonary artery catheterization after induction of general anaesthesia
Number of subjects: 20
Study: 9065315

Group type: EXPERIMENTAL
Intervention: New formulation of verapamil (Veramex 40)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard formulation of verapamil
Number of subjects: 16
Study: 1557803

Group type: EXPERIMENTAL
Intervention: Preoperative autologous blood donation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hemodilution
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 2860033

Group type: EXPERIMENTAL
Intervention: Delta Loop
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Delta T
Number of subjects: 246
Study: 31918437

Group type: EXPERIMENTAL
Intervention: Classroom nutrition education program
Number of subjects: 0
Study: 30231098

Group type: EXPERIMENTAL
Intervention: Dolder bar attachments (BOD)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Locator attachments (LOD)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Resilient telescopic attachments (TOD)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study: 26625270

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day
Number of subjects: 427

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 427

Group type: COMPARATOR
Intervention: Placebo/pioglitazone
Number of subjects: 427
Study: 23905576

Group type: EXPERIMENTAL
Intervention: Inhaled GS-9411 (2.4, 4.8, and 9.6 mg), dosed twice daily for 14 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Inhaled GS-9411
Number of subjects: 36
Study: 21926426

Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release (ER) 37.5 to 300 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20534179

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 2183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2183
Study: 18824828

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30, 50, or 70 mg/d
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study: 16874755

Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 12952496

Group type: EXPERIMENTAL
Intervention: BIA 2‐093 (20, 50, 100, 200, 400, 600, 900, 1200 mg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: BIA 2‐093
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 10648452

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14